Journal article icon

Journal article

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Abstract:
Background: Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer patients. Patients and methods: The dose of GSK2256098 was escalated, in cohorts of patients with advanced cancer, from 80 to 1500 mg, oral twice daily (BID), until the MTD was d... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1093/annonc/mdw427

Authors


More by this author
Department:
Oxford, MSD, Oncology
Role:
Author
Expand authors...
GlaxoSmithKline More from this funder
Publisher:
Oxford University Press Publisher's website
Journal:
Annals of Oncology Journal website
Volume:
27
Issue:
12
Pages:
2268-2274
Publication date:
2016-01-01
Acceptance date:
2016-10-17
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Pubs id:
pubs:656119
URN:
uri:6d65cebc-6d19-4620-96a4-2b3d5bdebd90
UUID:
uuid:6d65cebc-6d19-4620-96a4-2b3d5bdebd90
Local pid:
pubs:656119
Paper number:
12

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP